<DOC>
	<DOC>NCT00002133</DOC>
	<brief_summary>To assess the efficacy and safety of itraconazole oral solution in HIV-seropositive patients with oropharyngeal candidiasis that is refractory to fluconazole.</brief_summary>
	<brief_title>An Open Study of the Effect of Itraconazole Oral Solution for the Treatment of Fluconazole Refractory Oropharyngeal Candidiasis in HIV-Positive Subjects.</brief_title>
	<detailed_description>Patients receive itraconazole oral solution twice daily. Per 08/15/94 amendment, patients with complete resolution of oropharyngeal candidiasis lesions upon completion of treatment are eligible for maintenance treatment on protocol FDA 236C. Patients who decline maintenance are followed for 6 weeks. Patients who relapse during follow-up are re-treated for 14-28 days; if lesions clear, patients may enter the maintenance protocol.</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Candidiasis</mesh_term>
	<mesh_term>Candidiasis, Oral</mesh_term>
	<mesh_term>Itraconazole</mesh_term>
	<mesh_term>Hydroxyitraconazole</mesh_term>
	<mesh_term>Fluconazole</mesh_term>
	<criteria>Inclusion Criteria Patients must have: HIV antibody seropositivity or diagnosis of AIDS. Confirmed oropharyngeal candidiasis. Failed fluconazole treatment within the past 14 days. Life expectancy of at least 3 months. NO symptoms of esophageal candidiasis (e.g., dysphagia) unless endoscopic exam of esophagus was performed and fungal esophagitis was not present. NO prior disseminated candidiasis. Exclusion Criteria Coexisting Condition: Patients with the following symptoms or conditions are excluded: Underlying clinical condition that precludes study completion or places the patient at significant risk. Considered unreliable about following physician's directives. Concurrent Medication: Excluded: Investigational drugs (approved expanded access drugs are permitted). Rifampin. Rifabutin. Phenobarbital. Phenytoin. Carbamazepine. Terfenadine. Astemizole. Patients with the following prior conditions are excluded: History of hypersensitivity to imidazole or azole compounds. Clinical evidence of significant hepatic disease within the past 2 months. Prior Medication: Excluded: Investigational drugs within 1 month prior to study entry (approved expanded access drugs are permitted).</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 1996</verification_date>
	<keyword>Itraconazole</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>AIDS-Related Complex</keyword>
	<keyword>Candidiasis, Oral</keyword>
</DOC>